Zimmer Biomet - Catch-up Effects Lead to Strong Outlook!
Reading Time: 1 minute
Business Driver: Zimmer Biomet (ZMB) is particularly strong in knee and hip implants, as well as in the S.E.T segment (Surgical, Sports Medicine, Foot and Ankle, Extremities, and Trauma), and is currently benefiting from a continuing catch-up effect in routine surgeries. Mid-term, Zimmer Biomet should benefit from additional approvals for implant solutions after receiving the green light from the FDA for its anatomical OsseoFit Stemless Shoulder System. On February 11, the company surprised with a better-than-expected Q4 result, achieving an...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
